Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924376 | 0.94 | F2 (0.41) | F2ALDH1A1MAPK8IDO1P2RX7 | |
| SCHEMBL6926915 | 0.92 | F2 (0.39) | F2ALDH1A1MAPK8IDO1ACACB | |
| SCHEMBL6923524 | 0.91 | F2 (0.38) | F2ALDH1A1MAPK8IDO1P2RX7 | |
| SCHEMBL6924958 | 0.89 | F2 (0.39) | F2ALDH1A1MAPK8IDO1P2RX7 | |
| SCHEMBL6921482 | 0.88 | ALDH1A1 (0.38) | F2ALDH1A1MAPK8IDO1F10 | |
| SCHEMBL6926517 | 0.86 | F2 (0.49) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6928608 | 0.84 | ALDH1A1 (0.36) | F2ALDH1A1MAPK8IDO1PTGER1 | |
| SCHEMBL6925131 | 0.84 | F2 (0.44) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL6925270 | 0.84 | F2 (0.43) | F2ALDH1A1MAPK8IDO1PRSS1 | |
| SCHEMBL6926182 | 0.84 | TSHR (0.35) | F2ALDH1A1MAPK8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885ALDH1A1 4773/4885MAPK8 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.